Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
Would you hold HAI/ FUDR for SBRT of a residual liver metastasis following hepatic metastasectomy?
No further systemic therapy is planned for the time being.
Related Questions
Would having mucinous rectal adenocarcinoma impact your recommendation for short vs long course RT as part of a TNT regimen?
When treating rectal cancer with TNT and induction chemotherapy first, do you repeat pelvic MRI prior to planning for chemoradiation?
Do the results of recently presented ACCORD trial for EHC and gallbladder cancers have implications for your adjuvant treatment recommendations?
Are the results of CONKO-007 changing practice for the management of pancreatic cancer?
Would you recommend adjuvant radiotherapy in addition to chemotherapy in gastric adenocarcinoma s/p gastrectomy with a distal positive resection margin?
Is there a role for quad-shot or similar regimen in a patient with a technically resectable, but medically inoperable colon cancer that is both bleeding and causing a partial obstruction?
When treating with SBRT and immunotherapy for unresectable HCC, how do you sequence the treatment?
How likely is late radiation induced lumbosacral plexopathy from treatment of anal cancer with chemo-RT 20 years ago and how would you manage it?
Would you consider long course pelvic CRT after neoadjuvant chemotherapy in a patient with low lying, locally advanced rectal adenocarcinoma when you're unable to meet small bowel constraints?
What is your approach to pancreatic adenocarcinoma s/p surgery with N0/R0 disease and intermediate risk factors with regard to adjuvant chemo-radiation?